Site Editor

Thomas Flaig, MD


ESMO 2022: PD-L1 Expression in Dendritic Cells and Survival in Untreated Metastatic Urothelial Cancer

By: Kayci Reyer
Posted: Monday, September 19, 2022

According to a presentation at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract 1735O), dendritic cells that express PD-L1 may be associated with improved overall survival for some patients with bladder cancer who receive atezolizumab treatment. These findings are from an IMvigor130 exploratory analysis.

“These findings reinforce model system data demonstrating the particular importance of PD-L1–expressing [dendritic cells],” concluded Enrique Grande Pulido, MD, PhD, of MD Anderson Cancer Center Madrid, and colleagues.

The analysis focused on patients from arms B and C of the phase III IMvigor130 trial. Evaluable patients (n = 627) had been diagnosed with but had not received treatment of metastatic urothelial cancer. Patients had archival tumors that were analyzed using BioEval; tumors also underwent two PD-L1 assays: VENTANA SP142 and Dako 22C3. The SP142 assay differentiated between tumors with at least 5% immune cells and those with fewer than 5% immune cells. The 22C3 assay resulted in a combined positive score of up to 10.

The SP142 assay identified the preferential co-occurrence of PD-L1 and dendritic cells. This co-localization occurred with dendritic cells more than with other myeloid subsets. An association was noted between improved overall survival and at least 5% immune cells on SP142 and a 22C3 combined positive score of at least 10. A combined positive score of at least 10 but fewer than 5% immune cells was associated with the shortest median overall survival.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.